Skip to main content

Table 2 Procedures for one time cross-sectional study visit for the HIV-positive, ART-treated adults that participated in the Renal Risk Reduction (R3) study and now called back (n = 2,000)

From: Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design

Visit 1

-Screening, informed consent

-Blood pressure measurement

-Diabetes screeninga

-Enrollment (if meet eligibility criteria)

-Participant to provide urine specimen at study clinic on day of visit (for uACR and uAPR)

-Participant to provide urine specimen at study clinic on day of visit (for one-time uACR and uAPR)

Specimen collection (~ 3 tubes; ~ 15 mLs total)

i) Serum creatinine (3 mL gold top tube)

ii) HBVb and HCV testingc (leverage existing stored plasma aliquots)

iii) CMV testingd (leverage existing stored plasma aliquots)

iv) Additional specimens to store (Two urine aliquots: Two 3 mL EDTA tubes; toenail/hair samples from consenting patients)

  1. aScreen for diabetes (if symptomatic, e.g., polyuria, polydipsia, weight loss), perform fasting/random glucose test (point-of-
  2. care device) and if ≥ 6.1 mmol/L (110 mg/dL), then patient has possible diabetes, and is referred to medical
  3. provider/clinic for further evaluation
  4. bScreen initially with hepatitis B surface antigen, and if positive, perform hepatitis B e Ag and hepatitis B DNA (viral load)
  5. cScreen initially with hepatitis C antibody (due to anticipated low prevalence (< 1%), we will test a random sample of 200
  6. HIV-positive adults and perform additional screening (stored samples) only if prevalence > 2%)
  7. dScreen for Cytomegalovirus (CMV) using IgG antibody tests
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us